{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4"},{"groupId":"OG001","value":"11.4"},{"groupId":"OG002","value":"21.3"}]}],"title":"Statement a): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1"},{"groupId":"OG001","value":"12.7"},{"groupId":"OG002","value":"17.5"}]}],"title":"Statement a): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"8.9"},{"groupId":"OG002","value":"3.8"}]}],"title":"Statement a): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4"},{"groupId":"OG001","value":"26.6"},{"groupId":"OG002","value":"16.3"}]}],"title":"Statement a): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6"},{"groupId":"OG001","value":"22.8"},{"groupId":"OG002","value":"22.5"}]}],"title":"Statement a): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6"},{"groupId":"OG001","value":"13.9"},{"groupId":"OG002","value":"11.3"}]}],"title":"Statement a): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement a): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"6.3"}]}],"title":"Statement b): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"7.6"},{"groupId":"OG002","value":"10.0"}]}],"title":"Statement b): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"10.1"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement b): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3"},{"groupId":"OG001","value":"29.1"},{"groupId":"OG002","value":"27.5"}]}],"title":"Statement b): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3"},{"groupId":"OG001","value":"49.4"},{"groupId":"OG002","value":"41.3"}]}],"title":"Statement b): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement b): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement b): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"3.8"}]}],"title":"Statement c): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5"},{"groupId":"OG001","value":"7.6"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement c): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1"},{"groupId":"OG001","value":"17.7"},{"groupId":"OG002","value":"12.5"}]}],"title":"Statement c): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2"},{"groupId":"OG001","value":"29.1"},{"groupId":"OG002","value":"31.3"}]}],"title":"Statement c): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1"},{"groupId":"OG001","value":"36.7"},{"groupId":"OG002","value":"37.5"}]}],"title":"Statement c): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement c): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement c): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement d): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2"},{"groupId":"OG001","value":"8.9"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement d): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5"},{"groupId":"OG001","value":"17.7"},{"groupId":"OG002","value":"11.3"}]}],"title":"Statement d): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7"},{"groupId":"OG001","value":"29.1"},{"groupId":"OG002","value":"26.3"}]}],"title":"Statement d): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2"},{"groupId":"OG001","value":"36.7"},{"groupId":"OG002","value":"33.8"}]}],"title":"Statement d): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"5.0"}]}],"title":"Statement d): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"8.8"}]}],"title":"Statement d): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6"},{"groupId":"OG001","value":"15.2"},{"groupId":"OG002","value":"10.0"}]}],"title":"Statement e): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5"},{"groupId":"OG001","value":"16.5"},{"groupId":"OG002","value":"22.5"}]}],"title":"Statement e): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1"},{"groupId":"OG001","value":"17.7"},{"groupId":"OG002","value":"22.5"}]}],"title":"Statement e): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1"},{"groupId":"OG001","value":"19.0"},{"groupId":"OG002","value":"11.3"}]}],"title":"Statement e): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5"},{"groupId":"OG001","value":"20.3"},{"groupId":"OG002","value":"18.8"}]}],"title":"Statement e): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9"},{"groupId":"OG001","value":"7.6"},{"groupId":"OG002","value":"6.3"}]}],"title":"Statement e): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"8.8"}]}],"title":"Statement e): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"3.8"}]}],"title":"Statement f): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"3.8"}]}],"title":"Statement f): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7"},{"groupId":"OG001","value":"15.2"},{"groupId":"OG002","value":"16.3"}]}],"title":"Statement f): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1"},{"groupId":"OG001","value":"31.6"},{"groupId":"OG002","value":"32.5"}]}],"title":"Statement f): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0"},{"groupId":"OG001","value":"43.0"},{"groupId":"OG002","value":"35.0"}]}],"title":"Statement f): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement f): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"8.8"}]}],"title":"Statement f): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"5.0"}]}],"title":"Statement g): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"7.6"},{"groupId":"OG002","value":"11.3"}]}],"title":"Statement g): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7"},{"groupId":"OG001","value":"31.6"},{"groupId":"OG002","value":"23.8"}]}],"title":"Statement g): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4"},{"groupId":"OG001","value":"20.3"},{"groupId":"OG002","value":"22.5"}]}],"title":"Statement g): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4"},{"groupId":"OG001","value":"35.4"},{"groupId":"OG002","value":"27.5"}]}],"title":"Statement g): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"2.5"}]}],"title":"Statement g): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement g): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"5.0"}]}],"title":"Statement h): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8"},{"groupId":"OG001","value":"11.4"},{"groupId":"OG002","value":"16.3"}]}],"title":"Statement h): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5"},{"groupId":"OG001","value":"25.3"},{"groupId":"OG002","value":"23.8"}]}],"title":"Statement h): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1"},{"groupId":"OG001","value":"24.1"},{"groupId":"OG002","value":"16.3"}]}],"title":"Statement h): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2"},{"groupId":"OG001","value":"32.9"},{"groupId":"OG002","value":"27.5"}]}],"title":"Statement h): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"3.8"}]}],"title":"Statement h): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement h): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement i): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"3.8"}]}],"title":"Statement i): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"5.0"}]}],"title":"Statement i): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"22.5"}]}],"title":"Statement i): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4"},{"groupId":"OG001","value":"60.8"},{"groupId":"OG002","value":"60.0"}]}],"title":"Statement i): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement i): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"8.8"}]}],"title":"Statement i): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement j): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0"},{"groupId":"OG001","value":"8.9"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement j): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6"},{"groupId":"OG001","value":"10.1"},{"groupId":"OG002","value":"15.0"}]}],"title":"Statement j): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5"},{"groupId":"OG001","value":"22.8"},{"groupId":"OG002","value":"26.3"}]}],"title":"Statement j): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3"},{"groupId":"OG001","value":"53.2"},{"groupId":"OG002","value":"47.5"}]}],"title":"Statement j): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement j): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"8.8"}]}],"title":"Statement j): Answer Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"HCPs who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Question 2: \"If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Patients will be moved outside of infusion unit to receive FDC SC; b) FDC SC route will allow more flexible scheduling; c) More patients will be treated in the infusion unit; d) Waiting list for any P+H IV treatment at the infusion unit will be reduced; e) Staff resources will be redistributed to other departments of the hospital; f) There will still be sufficient interaction time between HCPs and patients; g) Staff will spend more time for further education/development; h) Staff will dedicate more time attending to administrative tasks for Perjeta-Herceptin patients; i) Patients will spend less time in the care unit; j) Administration by FDC SC injection is preferred by patients.\"","groups":[{"description":"This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Healthcare Professionals"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"A: P+H IV Followed by PH FDC SC"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG002","title":"B: PH FDC SC Followed by P+H IV"}],"paramType":"NUMBER","populationDescription":"The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 6 (each cycle is 21 days)","title":"Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Treatment Room","type":"SECONDARY","unitOfMeasure":"Percentage of HCPs"}